Examination for the effect of combination therapy with raloxifene and eldecalcitol in postmenopausal osteoporotic patients

Examination for the effect of combination therapy with raloxifene and eldecalcitol in postmenopausal osteoporotic patients - Examination for the effect of combination therapy with raloxifene and eldecalcitol in postmenopausal osteoporotic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008440

Enrollment

Registered

2012-08-01

Start date

2013-02-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Raloxifene (60mg/day) + eldecalcidol (0.75 &amp

micro

g/day) Raloxifene (60mg/day)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Postmenopausal osteoporotic patients. Patients who are treated with raloxifene for more than one year. Patients with informed of consent.

Exclusion criteria

Exclusion criteria: Patients who are diagnosed as contraindication of raloxifene treatments. Patients who are diagnosed as contraindication of eldecalcitol treatments. Patients who are inappropriate for this study by physician.

Design outcomes

Primary

Measure	Time frame
Change of lumbar spine bone mineral density	—

Secondary

Measure	Time frame
Change of total hip bone mineral density Number of fracture occurred Change of bone metabolic markers Effect of improve exercise function Safety	—

Countries

Japan

Contacts

Public ContactHiroo Matsuse

Kurume University, Medical Department Department of Orthopaedic Surgery

matsuse_hiroh@kurume-u.ac.jp0942-31-7568

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026